Search research articles
Contact Us
Filters
Showing results (201-210 of 256) with videos related to
Page
of 26
Sort By:
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association
|
August 10, 2016
Changing perceptions and efficacy of generic medicines: An intervention study
Sarah L E Colgan, Kate Faasse, Jennifer A Pereira, et al.
European Journal of Endocrinology
|
March 13, 2012
Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial
Andrew Grey, Vaughan Beckley, Anthony Doyle, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 13, 2005
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency
Andrew Grey, Jenny Lucas, Anne Horne, et al.
Addiction (Abingdon, England)
|
October 20, 2010
Decreased bone density in men on methadone maintenance therapy
Andrew Grey, Karla Rix-Trott, Anne Horne, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
September 13, 2017
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial
Andrew Grey, Mark J Bolland, Anne Horne, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
June 14, 2013
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial
Andrew Grey, Mark Bolland, Bobby Mihov, et al.
BMJ Open
|
March 21, 2013
Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial
Mark J Bolland, Alan Barber, Robert N Doughty, et al.
BMJ (Clinical Research Ed.)
|
September 16, 2024
Barriers to investigating and reporting research misconduct: prioritising publication integrity
Alison Avenell, Andrew A Klein, Jennifer A Byrne, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
Andrew Grey, Mark Bolland, Greg Gamble, et al.
Nature
|
July 29, 2024
Stop just paying lip service on publication integrity
Andrew Grey, Alison Avenell, Andrew A Klein, et al.
Page
of 26
Search research articles
Search
Showing results (201-210 of 256) with videos related to
Sort By:
Page
of 26
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association
|
August 10, 2016
Changing perceptions and efficacy of generic medicines: An intervention study
Sarah L E Colgan, Kate Faasse, Jennifer A Pereira, et al.
European Journal of Endocrinology
|
March 13, 2012
Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial
Andrew Grey, Vaughan Beckley, Anthony Doyle, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 13, 2005
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency
Andrew Grey, Jenny Lucas, Anne Horne, et al.
Addiction (Abingdon, England)
|
October 20, 2010
Decreased bone density in men on methadone maintenance therapy
Andrew Grey, Karla Rix-Trott, Anne Horne, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
September 13, 2017
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial
Andrew Grey, Mark J Bolland, Anne Horne, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
June 14, 2013
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial
Andrew Grey, Mark Bolland, Bobby Mihov, et al.
BMJ Open
|
March 21, 2013
Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial
Mark J Bolland, Alan Barber, Robert N Doughty, et al.
BMJ (Clinical Research Ed.)
|
September 16, 2024
Barriers to investigating and reporting research misconduct: prioritising publication integrity
Alison Avenell, Andrew A Klein, Jennifer A Byrne, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
Andrew Grey, Mark Bolland, Greg Gamble, et al.
Nature
|
July 29, 2024
Stop just paying lip service on publication integrity
Andrew Grey, Alison Avenell, Andrew A Klein, et al.
Page
of 26